These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8363169)

  • 1. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
    Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
    Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
    Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
    Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation.
    Viscoli C; Dudley M; Ferrea G; Boni L; Castagnola E; Barretta MA; Lanino E; Loy A; Moroni C; Somenzi M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():113-20. PubMed ID: 1856140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
    Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
    J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study.
    Meunier F; Van der Auwera P; Aoun M; Ibrahim S; Tulkens PM
    J Antimicrob Chemother; 1991 May; 27 Suppl C():129-39. PubMed ID: 1856142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Kern WV; Cometta A; De Bock R; Langenaeken J; Paesmans M; Gaya H
    N Engl J Med; 1999 Jul; 341(5):312-8. PubMed ID: 10423465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
    Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
    Pession A; Prete A; Paolucci G
    Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
    ; Calandra T; Klastersky J; Gaya H; Glauser MP; Meunier F; Zinner SH
    N Engl J Med; 1987 Dec; 317(27):1692-8. PubMed ID: 2892130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
    Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
    Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.
    J Infect Dis; 1991 May; 163(5):951-8. PubMed ID: 2019772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
    Finley RS; Fortner CL; deJongh CA; Wade JC; Newman KA; Caplan E; Britten J; Wiernik PH; Schimpff SC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):193-7. PubMed ID: 6765414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.